Results 141 to 150 of about 214,341 (267)

<i>AXL</i>-mRNA Overexpression in Size-Based Enriched Circulating Tumor Cells as a Potential Biomarker for Anti-AXL Targeted Therapies in Non-Small-Cell Lung Cancer. [PDF]

Cancers (Basel)
Ntzifa A, Themistokli E, Strati A, Zavridou M, Tsaroucha E, Sfika A, Psyrri A, Balgouranidou I, Kotsakis A, Georgoulias V, Lianidou E.   +10 more
europepmc   +1 more source

Artificial Intelligence for Identifying Tumor‐Reactive CD8+ T Cells: Biological Principles, Computational Advances, and Future Directions

Med Research, EarlyView.
This review details a three‐stage paradigm shift for tumor‐reactive CD8+ T‐cell identification: decoding transcriptomic states, deciphering clonal functional efficacy, and molecular‐level therapeutic TCR design. Addressing translational hurdles and generative AI “scientific blind spots”—such as missing catch bonds—we present a visionary roadmap.
Chao Yang, Yingying Sun, Yan Zhang, Yifen Shi, Zhiwen Shi   +4 more
wiley   +1 more source

Molecular Analysis of EBUS-TBNA Samples for Nodal Staging in Non-Small Cell Lung Cancer. [PDF]

Cancers (Basel)
Ehab A, Benabdallah N, Darwiche K.
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Treatment of oligometastatic lung cancers: new data, new drivers, new approaches. [PDF]

BMJ Oncol
O'Dwyer N, Palma DA.
europepmc   +1 more source

Diffuse Skin Sclerosis in a Patient With Lung Cancer

JEADV Clinical Practice, EarlyView.
Anna‐Sophia Leven, Eva Hadaschik, Alpaslan Tasdogan   +2 more
wiley   +1 more source

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic <i>HER2</i>-Mutant Non-Small Cell Lung Cancer. [PDF]

JCO Precis Oncol
Lovly CM, Baik C, Nagasaka M, Patil T, Maruti SS, Stanhope S, Kaya NA, Herbertz S, Nordstrom B, Evans K, Le X.   +10 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Nanoparticle polymeric micellar paclitaxel compared with paclitaxel for advanced esophageal squamous cell carcinoma

Precision Medical Sciences, EarlyView.
The nanoparticle polymeric micellar paclitaxel plus nedaplatin regimen demonstrates superior efficacy and tolerable toxicities compared to the paclitaxel–nedaplatin combination as a first‐line treatment for advanced esophageal squamous cell carcinoma.
Yu‐Qing Cao, Meng Song, Bing‐jie Xue, Fei‐Yu Wang, Xiang‐Ming Huang, Jie Cao, Ai‐Guo Cao, Xin‐En Huang   +7 more
wiley   +1 more source

Editorial: The role of circular RNAs and MicroRNAs in non-small cell lung cancer: from mechanisms to therapeutic potential. [PDF]

Front Oncol
Tirpe A, Campomenosi P, Berindan-Neagoe I.   +2 more
europepmc   +1 more source